ArticleMicrobial cell factories2020
De novo resveratrol production through modular engineering of an Escherichia coli-Saccharomyces cerevisiae co-culture.
Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 110 citations in OpenAlex.
- Metabolic Engineering Strategies for Flavonoid Biosynthesis in Saccharomyces cerevisiae: Current Advances and Future Perspectives.Biotechnology and bioengineering · 2026Review
- Programmable cell-cell adhesion in synthetic yeast communities for improved bioproduction.Nature chemical biology · 2026Article
- Cooperativity in microbial biotechnology: synthetic consortia as emerging metabolic engineering strategy for sustainable bioproduction.Frontiers in bioengineering and biotechnology · 2026Review
- Recent advances of muconic acid production using microbial synthetic biology.Archives of microbiology · 2025Review
- Natural anti-cancer products: insights from herbal medicine.Chinese medicine · 2025Review
- PYF: a multi-functional algorithm for predicting production and optimizing metabolic engineering strategy in Escherichia coli microbial consortia.Briefings in bioinformatics · 2025Article
- Review
- Biotechnological Breakthroughs in Resveratrol Synthesis and Health Advancements.Current pharmaceutical biotechnology · 2025Review
- CRISPR/Cas9-mediatedHorticulture research · 2025Article
- Algorithm of spatial-temporal simulation for environment-strain interactions in strain-strain consortia based on resource competition mechanism.Computational and structural biotechnology journal · 2024Article
- New insights into the roles of fungi and bacteria in the development of medicinal plant.Journal of advanced research · 2024Review
- Metabolic engineering of Corynebacterium crenatum for enhanced L-tyrosine production from mannitol and glucose.Microbial cell factories · 2024Article
- Integration of co-culture and transport engineering for enhanced metabolite production.Plant biotechnology (Tokyo, Japan) · 2024Article
- The repertoire and levels of secondary metabolites in microbial cocultures depend on the inoculation ratio: a case study involving Aspergillus terreus and Streptomyces rimosus.Biotechnology letters · 2024Article
- Denovo Production of Resveratrol by Engineered Rice Wine StrainJournal of fungi (Basel, Switzerland) · 2024Article
- De Novo Synthesis of Resveratrol from Sucrose by Metabolically EngineeredBiomolecules · 2024Article
- Efficient conversion of aromatic and phenylpropanoid alcohols to acids by the cascade biocatalysis of alcohol and aldehyde dehydrogenases.Synthetic and systems biotechnology · 2024Article
- Hexadecanoic acid produced in the co-culture of S. cerevisiae and E.coli promotes oxidative stress tolerance of the S.cerevisiae cells.World journal of microbiology & biotechnology · 2024Article
- Efficient Biosynthesis of Salidroside via ArtificialACS omega · 2024Article
- A molecular toolkit of cross-feeding strains for engineering synthetic yeast communities.Nature microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundResveratrol is a plant secondary metabolite with diverse, potential health-promoting benefits. Due to its nutraceutical merit, bioproduction of resveratrol via microbial engineering has gained increasing attention and provides an alternative to unsustainable chemical synthesis and straight extraction from plants. However, many studies on microbial resveratrol production were implemented with the addition of water-insoluble phenylalanine or tyrosine-based precursors to the medium, limiting in the sustainable development of bioproduction.
resultsHere we present a novel coculture platform where two distinct metabolic background species were modularly engineered for the combined total and de novo biosynthesis of resveratrol. In this scenario, the upstream Escherichia coli module is capable of excreting p-coumaric acid into the surrounding culture media through constitutive overexpression of codon-optimized tyrosine ammonia lyase from Trichosporon cutaneum (TAL), feedback-inhibition-resistant 3-deoxy-d-arabinoheptulosonate-7-phosphate synthase (aroG
conclusionsThis is first study that demonstrates the use of a synthetic E. coli-S. cerevisiae consortium for de novo resveratrol biosynthesis, which highlights its potential for production of other p-coumaric-acid or resveratrol derived biochemicals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.